Paving the way to personalized genomic medicine: Steps to successful implementation

Current Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 2, 2009, Pages 125-132

  Fackler, J L ^a   McGuire, A L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Ethics; Genomics; Personalized genomic medicine; Personalized medicine; Policy

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; FUNDING; GENE SEQUENCE; GENETIC VARIABILITY; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH EDUCATION; HEALTH INSURANCE; INDIVIDUALIZATION; INTERPERSONAL COMMUNICATION; MEDICAL GENETICS; MEDICAL INFORMATICS; METABOLOMICS; OUTCOMES RESEARCH; PERSONALIZED GENOMIC MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PROTEOMICS; REVIEW; UNITED STATES;

EID: 70449685099     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569209788653998     Document Type: Review

References (82)

1. Henig RM. High-Tech Fortunetelling. The New York Times 24 December 1989; 6.
2. S.3822. Genomics and Personalized Medicine Act of 2006 (2006). http://www.dnapolicy.org/resources/Obama-Genomics-Personalized-Medicine-Act- 2006.pdf and http://thomas.loc.gov/cgi-bin/query/z?c109:s3822: [Accessed March 5, 2009].
3. DHHS. Personalized Healthcare: Pioneers, Partnership, Progress (2008). http://www.hhs.gov/myhealthcare/news/phc-2008-report.pdf [Accessed March 5, 2009].
4. DHHS. HHS Priority Activities (NDa). http://www.hhs.gov/500DayPlan/ priorities.html [Accessed March 5, 2009].
5. Lovgren S. Personalized Medicine Promises Tailor-Made Diagnoses, Treatments (2006). http://news.nationalgeographic.com/news/2006/10/061018- personal-medicine.html [Accessed March 5, 2009].
6. Rowe A. Where's my Personalized Medicine? (2007). http://www.wired.com/ medtech/drugs/news/2007/03/72860 [Accessed March 5, 2009].
7. Rischer J. Personalized Medicine: The Promise and Realities of Healthcare Tailored to You (2008). http://healthfieldmedicare.suite101.com/article.cfm/ personalized-medicine [Accessed March 5, 2009].
8. DHHS. Personalized Healthcare: Opportunities, Pathways, Resources (2007). http://www.hhs.gov/myhealthcare/news/phc-report.pdf [Accessed March 5, 2009].
9. Jain K. Personalized Medicine. Curr Opin Mol Ther 2002; 4(6): 548-558
10. Yeatman TJ, Mule J, Dalton WS, et al. On the eve of personalize medicine in oncology. Cancer Res 2008; 28: 7250-7252
11. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291(5507): 1304-1351
12. NHGRI. All About the Human Genome Project (2008). http://www.genome.gov/ 10001772 [Accessed March 5, 2009].
13. Wadman M. James Watson's genome sequenced at high speed. Nature 2008; 452: 788 (Pubitemid 351550830)
14. Bentley DR, Balasubramanian S, Swerdlow HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008; 456: 53-59
15. Wang J, Wang W, Li R, et al. The diploid genome sequence of an Asian individual. Nature 2008; 456: 60-65
16. Karow J. Genome X Prize Guidelines Hint at High Standards; Rules to be Finalized by April. GenomeWeb (2006). http://www.genomeweb.com/issues/news/ 136791-1.html [Accessed March 5, 2009].
17. Vanier V. National physician group MDVIP partners with Navigenics. The Navigator (2008). http://blog.navigenics.com/articles/comments/national- physician-group-mdvip-partners-with-navigenics/ [Accessed March 5, 2009].
18. FeeroWG, Guttmacher AE, Collins FS. The genome gets personal--almost. JAMA 2008; 299(11): 1351-1352
19. McGuire A, Burke W. An unwelcome side effect of direct-to-consumer personal genome testing. JAMA 2008; 300: 2669-2671
20. Belhajjame K, Embury SM, Fan H, et al. Proteome Data Integration: Characteristics and Challenges. Proceedings of the UK e-Science All Hands Meeting in Nottingham, UK 2005.
21. Grassi R, Lagalla R, Rotondo A. Genomics, proteomics, MEMS and SAIF: which role for diagnostic imaging? Radiol Med 2008; 113: 775-778
22. Daviss B. Growing pains for metabolomics. Scientist 2005; 19(8): 25-28
23. Ceglarek U, Leichtlea A, Brugela M, et al. Challenges and developments in tandem mass spectrometry based clinical metabolomics. Mol Cell Endocrinol 2008; 301(1-2): 266-271
24. DHHS. Realizing the Potential of Pharmacogenomics: Opportunities and Challenges (2008). http://www4.od.nih.gov/oba/SACGHS/reports/SACGHS-PGx-Report. pdf [Accessed March 5, 2009].
25. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23(36): 9312-9318
26. Beverage JN, Sissung TM, Sion AM, et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007; 96(9): 2224-2231
27. Rost S, Fregin A, Ivaskevicius V, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Nature 2004; 427(6974): 537-541
28. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5(4): 262-270 (Pubitemid 41131718)
29. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358(10): 999-1008. (Pubitemid 351347099)
30. Lesko LJ. The critical path of warfarin dosing: Finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 2008; 84(3): 301-303
31. Phillips K. Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 2008; 300(21): 2542-2544
32. Phillips KA, Liang SY, Van Bebber S, et al. Challenges to the translation of genomic information into clinical practice and health policy: Utilization preferences and economic value. Curr Opin Mol Ther 2008; 10(3): 260-266 (Pubitemid 351799277)
33. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008; 59: 1-12. (Pubitemid 351287920)
34. Surh LC, Lesko LJ, Hobbs S, et al. Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with 'what-ifs'. Pharmacogenomics 2009; 10(1): 137-147
35. Baudhuin L. Warfarin pharmacogenetics. Clinical Laboratory News (2008). http://www.aacc.org/publications/cln/2008/feb/Pages/series-0208.aspx [Accessed March 5, 2009].
36. Allison M. Is personalized medicine finally arriving? Nat Biotechnol 2008; 26(5): 509-517
37. PMC News Release 10/14/08. Personalized Medicine Coalition Applauds New Report 2008.
38. PWC. Personalized Medicine: The Emerging Pharmacogenomics Revolution (2005). www.pwc.com/techforecast/pdfs/pharmaco-wbx.pdf [Accessed March 5, 2009].
39. Lechleiter J. Markets of One: The Pharmaceutical Industry and The Pursuit of Personalized Medicine (2007). http://www.lilly.com/news/speeches/112907- speech-jl-harvard.html [Accessed March 5, 2009].
40. Lilly. Providing Value to Patients and Society (2007). http://www.lilly.com/about/citizenship/Lilly-corp-reprt-25.pdf [Accessed March 5, 2009].
41. Park R. GE, Eli Lilly team up on personalized medicine. IVD Technology Website (2008). http://www.devicelink.com/ivdt/archive/08/01/002.html [Accessed March 5, 2009].
42. Hayajneh Y. Health Informatics (ND). http://hayajneh.org/glossary/ vocabulary/h/Health-Informatics.html [Accessed March 5, 2009].
43. HP. HP Supports 'Individualized Medicine' Initiative at Partners HealthCare (2003). http://www.hp.com/hpinfo/newsroom/press/2003/030930a.html [Accessed March 5, 2009].
44. HP. Harvard/Partners Center for Genetics and Genomics Uses HP Solutions to Speed Biomedical Analysis, Collaboration Among Researchers (2005). http://www.hp.com/hpinfo/newsroom/press/2005/050215b.html?jumpid=reg-R1002-USEN [Accessed March 5, 2009].
45. HP. Collaborating to Create Personalized Medicine (ND). http://h71028.www7.hp.com/erc/downloads/HPCaseStudy-final.pdf [Accessed March 5, 2009].
46. Microsoft. New Alliance of Technology Companies and Research Organizations Seeks to Personalize Medicine (2006). http://www.microsoft.com/ presspass/features/2006/oct06/10-19BioIT.mspx [Accessed March 5, 2009].
47. Microsoft. Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment (2007). http://www.microsoft.com/presspass/press/2007/Sep07/09- 20MoffittAzyxxiPR.mspx [Accessed March 5, 2009].
48. PWC. The Factors Fueling Rising Health Care Costs 2006 (2006). http://www.ahip.org/redirect/PwCCostOfHC2006.pdf [Accessed March 5, 2009].
49. PHRMA. Drug Discovery and Development: Understanding the R&D Process (2007). http://www.phrma.org/files/RD%20Brochure%20022307.pdf [Accessed March 5, 2009].
50. Birmingham K. Experts predict bleak post-genomic era for drug R&D. Nat Med 2001; 7(3): 262. (Pubitemid 32224320)
51. Deloitte. Where is the ROI for targeted therapies? (2009) http://www.deloitte.com/dtt/article/0,1002,sid%253D80772%2526cid%253D177909,00. html [Accessed March 5, 2009].
52. NHGRI. Genetics, prevention and treatment (2008). http://www.genome.gov/ 19016938 [Accessed March 5, 2009].
53. Draborg E, Gyrd-Hansen D, Poulsen PB, et al. International comparison of the definition and the practical application of health technology assessment. Int J Technol Assess Health Care 2005; 21(1): 89-95. (Pubitemid 40229373)
54. Gallio D, Berto P. Health technology assessment (HTA): definition, role and use in the changing healthcare environment. Eur Ann Allergy Clin Immunol 2007; 39: 7-11.
55. NHS. UK National Health Service R&D Health Technology Assessment Programme 2003.
56. Nemeth LS, Wessell AM, Jenkins RG, et al. Strategies to accelerate translation of research into primary care within practices using electronic medical records. J Nurs Care Qual 2007; 22(4): 343-349
57. Nishisaki A, Keren R, Nadkarni V. Does simulation improve patient safety?: Self-efficacy, competence, operational performance, and patient safety. Anesthesiol Clin 2007; 25(2): 225-236
58. Devine EB, Wilson-Norton JL, Lawless NM, et al. Characterization of prescribing errors in an internal medicine clinic. Am J Health Syst Pharm 2007; 64(10): 1062-1070 (Pubitemid 46801538)
59. AHRQ. Health Technology Assessment (2008). http://www.ahrq.gov/browse/ techassm.htm [Accessed March 5, 2009].
60. CL. Browse the Health Technology Assessment Database (2008). http://mrw.interscience.wiley.com/cochrane/cochrane-clhta-articles-fs.html [Accessed March 5, 2009].
61. HSTAT. Health Services/Technology Assessment Text (2008). http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat [Accessed on March 5, 2009].
62. Myers ER, Havrilesky LJ, Kulasingam SL, et al. Genomic tests for ovarian cancer detection and management. Evidence Report/Technology Assessment No. 145. AHRQ Publication No. 07-E001. Rockville, MD: Agency for Healthcare Research and Quality (2006). http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1b.section. 94811 [Accessed March 5, 2009].
63. Emanuel EJ, Fuchs VR, Garber AM. Essential elements of a technology and outcomes assessment initiative. JAMA 2007; 298(11): 1323-1325
64. Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9(10): 665-674
65. Jones D. Steps on the road to personalized medicine (2007). http://www.nature.com/nrd/journal/v6/n10/full/nrd2434.html [Accessed March 5, 2009].
66. Teagarden JR, Moyer T. Medco-Mayo Warfarin Study (2008). http://www.hhs.gov/healthit/ahic/materials/04-08/phc/teagarden-files/800x600/ index.html [Accessed March 5, 2009].
67. NIH. Transformative R01 Program (ND). http://nihroadmap.nih.gov/T-R01/ [Accessed March 5, 2009].
68. AAAS and FDLI. What is Personalized Medicine? (2008) http://www.fdli.org/ conf/handouts/Primer-PM.pdf [Accessed March 5, 2009].
69. DHHS. Personalized Health Care (NDb). http://www.hhs.gov/myhealthcare/ index.html [Accessed March 5, 2009].
70. PMC. About PMC - Mission and Goals (ND). http://www. personalizedmedicinecoalition.org/about/mission-goals.php [Accessed March 5, 2009].
71. SACGHS. US System of Oversight of Genetic Testing (2008). http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS-oversight-report.pdf [Accessed March 5, 2009].
72. PMC. The Case for Personalized Medicine (2006). http://www. ageofpersonalizedmedicine.org/objects/pdfs/TheCaseforPersonalizedMedicine-11-13. pdf [Accessed March 5, 2009].
73. Baars MJH, Henneman L,ten Kate LP. Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: A global problem. Genet Med 2006; 7(9): 605-610
74. Harvey EK, Fogel CE, Peyrot M, et al. Providers' knowledge of genetics: A survey of 5915 individuals and families with genetic conditions. Genet Med 2007; 9(5): 259-267 (Pubitemid 46788191)
75. SACGHS. Genetics, Education and Training of Health Professionals (2004). http://oba.od.nih.gov/SACGHS/sacghs-focus-education.html [Accessed March 5, 2009].
76. Guttmacher AE, Porteous ME, McInerney JD. Educating healthcare professionals about genetics and genomics. Nat Rev Genet 2007; 8: 151-157
77. Emery J, Kumar S, Smith H. Patient Understanding of genetic principles and their expectations of genetic services within the NHS: A qualitative study. Commun Genet 1998; 1: 78-83.
78. Saukko PM, Ellard S, Richards SH, et al. Patients' understanding of genetic susceptibility testing in mainstream medicine: qualitative study on thrombophilia. BMC Health Serv Res 2007; 7: 82. (Pubitemid 47029966)
79. Condit CM, Ofulue N, Sheedy KM. Determinism and mass-media portrayals of genetics. Am J Hum Genet 1998; 62(4): 979-984
80. NHGRI. Applying genomics to clinical problems-diagnostics, preventive medicine, pharmacogenomics (2008). http://www.genome.gov/27529204 [Accessed March 5, 2009].
81. PMC News Release. Personalized Medicine Coalition announces major conferences (2008).
82. FDLI. Personalized Medicine: Promises and Challenges (ND). http://www.fdli.org/conf/435/ [Accessed March 5, 2009]